News |

These insights highlight the crucial role of systemic therapies in the comprehensive management of moderate to severe atopic dermatitis.

As cold weather is approaching for much of the country, it is crucial for dermatologists, pediatricians, and families to work together for proper pediatric atopic dermatitis care.

In a cohort of patients in the UK, investigators found that SARS-CoV-2 was associated with increased incidence of several immune-mediated inflammatory diseases, with psoriasis among them.

The addition of an HS dataset adds approximately 26,000 new patient records.

The September 2023 issue of Dermatology Times featured a spotlight on psoriasis research, advances, and treatment options in patients with skin of color. Learn more about the topics covered in each spotlight article.

Brauer’s textbook can be purchased through Amazon and Barnes & Noble.

Check in throughout the month to learn more about the latest treatment pearls and research findings in DermIQ’s spotlight on atopic dermatitis.

Investigators reported successful treatment of psoriasis with risankizumab, despite presence of concomitant HIV infection in 4 male patients.

No concerns were cited about the clinical data package, safety, or label of lebrikizumab.

Prepare your patients with helpful resources each week throughout National Eczema Awareness Month.

New and emerging therapies to treat a variety of skin conditions were presented by George Martin, MD, and Ted Rosen, MD.

Raj Chovatiya, MD, PhD, shares his atopic dermatitis insights.

October is Eczema Awareness Month and Dermatology Times is recognizing research to best serve patients with the most common type of eczema, atopic dermatitis.

Keep up with the latest headlines in dermatology from the past week, including new research into artificial intelligence skin tone bias, dermatologic care of the unhoused patient population, and more.

The hair guru explains how he opened up the first dermatology practice dedicated to hair, pearls from his session, innovative therapies, and research he has recently submitted.

Colleen Cotton, MD, does a deep dive on pediatric atopic dermatitis and explains the importance of timing and conversations with patients about different treatments.

Trifarotene emerges as an effective and well-tolerated solution for acne across diverse populations.

Learn more about the in-depth topics covered in the September 2023 Frontline Forum BCC management supplement of Dermatology Times.

The distribution of eyebrow and eyelash hair loss in relation to the severity of scalp hair loss remains underexplored, and this study established baseline characteristics.

Late-breaking data, oral presentations, and ePosters from Incyte’s dermatology portfolio will be presented in Berlin, Germany, October 11-14.

Matthew Zirwas, MD, addressed solutions to the toll consistent handwashing, sanitizing, and wearing gloves can take on hands.

Researchers found that continued use of once-daily subantibiotic dose oral doxycycline 40 mg modified-release capsules significantly reduced the relapse rate and inflammatory lesion counts in patients with moderate-to-severe rosacea.

We had the chance to catch up with Serrao before he took the stage and he explained why dermatology clinicians should keep their eyes on bimekizumab’s data and shared opportunities for further research.

NPs and PAs in dermatology are encouraged to monitor their own cardiovascular health and support their peers.

Learn more about the in-depth topics covered in the September 2023 print issue of Dermatology Times.

The survey conducted by Almirall included participants in the US and Europe.

In a Q&A, she shares pearls from her personal experiences treating pediatric acne and other underlying conditions that may require a multidisciplinary plan.

The intense itching associated with prurigo nodularis significantly affects patients’ quality of life, leading to higher rates of anxiety, depression, and sleep disturbances.

Leaders in dermatology shared a review of thought-provoking literature published this year to consider in practice, diagnostic solutions, and treatment strategies.

The phase 3 trial of once-daily roflumilast foam has shown promising results in the treatment of seborrheic dermatitis.